Uncontrolled, Open-Label Pre-Dinner Administration of Elobixibat in Japanese Adults with Chronic Constipation: A Retrospective Chart Review
Background: Elobixibat has been approved as a new therapeutic drug for chronic constipation. Only the pharmacological efficacy and safety profile of pre-breakfast administration of elobixibat had been previously demonstrated. Objective: We evaluated the efficacy and safety profile of pre-dinner admi...
Main Authors: | Takeo Odaka, MD, PhD, Kazunari Tominaga, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | Current Therapeutic Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0011393X20300424 |
Similar Items
-
Efficacy and safety of elobixibat in hemodialysis patients with chronic constipation: a retrospective study
by: Takefumi Shono, et al.
Published: (2020-04-01) -
Efficacy and Safety of Elobixibat in Elderly Patients with Chronic Constipation: A Single-center, Observational Study
by: Tatsuya Abe, et al.
Published: (2020-07-01) -
Cyclical constipation
by: C. K. Adarsh, et al.
Published: (2014-07-01) -
Functional constipation and posture in defecation
by: Fahrul Azmi Tanjung, et al.
Published: (2013-04-01) -
Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study
by: Daigo Kamei, et al.
Published: (2020-01-01)